RE:RE:RE:RE:RE:RE:Theralase Technologies as yet undiscoveredThe 1000% batting avg Skier59 was referring to was for the NMIBC Ph. 1b.
Since the optimized procedure, p#5 and p#6 are both cancer free in 1 single one-hour treatment. Not bad, isn't it?
Are you also focused, just like BionicBlowJob, on the past?
Do you think that we're all here for the TLC-2000 or for the oncology division? lolll
By the way, the TLC-2000 re-design is still on the agenda, as per the latest MD&A. And the COLD Laser therapy will allow them to pre-treat cancer patients, as per the 2 press release of Nov. 27 and Nov. 30 2017, to reverse the Warburg effect. There's even an upcoming presentation on this:
Photobiomodulation inhibits Warburg metabolism and potentiates a dose dependent response by glioblastoma cells to ruthenium-based photodynamic therapy Paper 11070-353 Time: 4:30 PM - 6:30 PM Author(s): Mark Roufaiel, Theralase Technologies, Inc. (Canada), Univ. Health Network (Canada); Arkady Mandel, Theralase Technologies, Inc. (Canada); Lothar D. Lilge, Univ. of Toronto (Canada), Univ. Health Network (Canada) Cancer cells reprogram their metabolism to promote tumorigenesis and increase drug resistance, through the Warburg Effect. The impact of PBM on the Warburg Effect and antineoplastic treatment such as PDT in glioblastoma cells was investigated. Dose dependent PBM mediated decreased glycolysis, increased oxidative phosphorylation, altered cellular proliferation rate, and induced a biphasic response in mRNA expression of multiple cancer genetic markers. These changes are reflected in the efficacy of antineoplastic therapies, here TLD1433-mediated PDT, whereby the efficacy changes also showed a biphasic response, which was not affected by CCO and ROS inhibition, suggesting a CCO and ROS independent mechanism.